ClinicalTrials.gg
Not yet recruitingNCT07772102TelesDystociaUpdated Aug 19, 2026

TelesDystocia: Tele-Support vs. Cognitive Aid in Simulated Shoulder Dystocia

An interventional study of Remote Tele-Support and Cognitive Aid in Shoulder Dystocia, sponsored by Medical University of Vienna. Not yet recruiting at 1 site in Austria. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Medical University of Vienna · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Shoulder dystocia is an unpredictable, time-critical obstetric emergency requiring immediate recognition and rapid execution of established maneuvers. To date, there is no published evidence evaluating remote real-time support for the management of shoulder dystocia, which could be especially relevant for providers not frequently confronted with obstetric emergencies.

This prospective, randomized, controlled, simulation-based trial compares healthcare providers' performance in managing a standardized shoulder dystocia scenario when supported by remote tele-assistance versus a standard cognitive aid. Teams of at least two healthcare providers manage a standardized scenario on the Laerdal MamaBirthie Task Trainer, with a trained study team member playing the laboring patient. Successful delivery requires completion of three predefined external maneuvers and one internal maneuver.

Teams are randomized to Group A (cognitive aid: a standardized visual reference tool with written instructions and pictograms) or Group B (remote tele-support: live video guidance from a credentialed obstetric expert via Signal). The primary outcome is the total performance score (0-25 points). Secondary outcomes include cognitive load (NASA-TLX), usability (System Usability Scale), and subjective experience and communication quality (5-point Likert scales).

02

Conditions studied

  • Shoulder Dystocia
03

In context

Lead sponsor

Medical University of Vienna is the lead sponsor of 1,109 studies on the registry; 184 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult healthy healthcare providers (paramedics, emergency physicians, midwives, nurses)
  • Working in teams of at least two persons
  • Fluent in German (the cognitive aid is provided in German)

Exclusion criteria

Exclusion:

  • Training in shoulder dystocia management (McRoberts, suprapubic pressure, Gaskin) in the preceding six months
  • Not fluent in German
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Active comparator
    Group A: Cognitive Aid

    Teams manage the standardized shoulder dystocia scenario supported by a standardized visual cognitive aid (written instructions and pictograms of the required external and internal maneuvers). No additional clinical assistance is provided after scenario initiation.

    Other: Cognitive Aid

  • Experimental
    Group B: Remote Tele-Support

    Teams manage the standardized shoulder dystocia scenario supported by live real-time video guidance from a credentialed obstetric expert via a study-issued mobile device using Signal.

    Other: Remote Tele-Support

Interventions

  • OtherRemote Tele-Support

    Live real-time video guidance provided by a credentialed obstetric expert (midwife or obstetrician) via a study-issued mobile device using Signal (GDPR-compliant secure video call) throughout the standardized shoulder dystocia scenario.

  • OtherCognitive Aid

    A standardized visual reference tool provided at the start of the scenario, containing concise written instructions and pictograms illustrating the three required external maneuvers and the single internal maneuver. No additional clinical assistance is provided after scenario initiation.

06

What researchers measure

Primary outcomes

  1. Total performance score

    Total performance score for the management of the standardized shoulder dystocia scenario (range 0-25 points; higher scores indicate better performance).

    Time frame: At completion of the simulated shoulder dystocia scenario

Secondary outcomes

  1. Cognitive load (NASA-TLX)

    NASA Task Load Index (0-20 points across 6 subcategories; higher scores indicate higher cognitive load).

    Time frame: Immediately after the simulated scenario

  2. Usability (System Usability Scale, SUS)

    Usability of the randomized support tool measured on the System Usability Scale (10 items, 1-5 points each).

    Time frame: Immediately after the simulated scenario

  3. Subjective experience (Likert)

    Participants' subjective experience assessed using a 5-point Likert scale (range 1-5; higher scores indicate greater confidence in the shoulder dystocia algorithm and better perceived overall performance in the simulation).

    Time frame: Immediately after the simulated scenario

  4. Communication quality (Likert)

    Quality of communication of the tele-support on a 5-point Likert scale, reported by the participant as well as by the expert.(range 1-5; higher scores indicate better quality of communication)

    Time frame: Immediately after the simulated scenario

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Dec 2026, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2026
First posted
Aug 19, 2026
StartEst.
Aug 25, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Jan 30, 2027
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07772102
Responsible party
Mathias Maleczek (Principal Investigator, Medical University of Vienna) — Principal investigator
First posted
Aug 19, 2026
Start date
Aug 25, 2026 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Aug 19, 2026

Study contacts

Mathias Maleczek, MD
Contact
mathias.maleczek@meduniwien.ac.at
+4314040041020
Bernhard Rössler, MD
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion